Keyphrases
3-hydroxy-3-methylglutaryl-CoA Reductase
14%
Adverse Events
71%
Cardiovascular Events
14%
Cardiovascular Risk
14%
Cell Dysfunction
14%
Cholesterol Reduction
14%
Clinical Trials
14%
Cognitive Impairment
28%
Drug Association
14%
Dysregulation
14%
Glucose Metabolism
14%
High Risk
14%
Increasing Prevalence
14%
Lipid Metabolism
14%
Lipid-lowering Therapy
14%
Long-term Safety
14%
Low-density Lipoprotein Cholesterol (LDL-C)
14%
Low-density Lipoprotein Cholesterol Level
14%
N-methyl-D-aspartate Receptor (NMDAR)
14%
Narrative Review
100%
Neurocognitive
85%
Neurocognitive Assessment
14%
Neurocognitive Effects
100%
Neuronal Cells
14%
Patient Characteristics
14%
Phase II Trial
28%
Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors
100%
Receptor Modulation
14%
Reductase Inhibitors
14%
Statins
14%
United States Food
14%
Medicine and Dentistry
Adverse Event
71%
Cardiovascular Risk
14%
Cardiovascular System
14%
Clinical Trial
14%
Clinician
14%
Cognitive Defect
28%
Dextro Aspartic Acid
14%
Glucose Metabolism
14%
Lipid Metabolism
14%
Low Density Lipoprotein Cholesterol
28%
Oxidoreductase
14%
Prevalence
14%
Proprotein Convertase 9
100%
Prospective Study
14%
Receptor Modulation
14%
Statin
14%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
71%
Cardiovascular Risk
14%
Clinical Trial
14%
Cognitive Defect
28%
Dextro Aspartic Acid
14%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
14%
Low Density Lipoprotein Cholesterol
28%
Oxidoreductase
14%
Prevalence
14%
Proprotein Convertase 9
100%
Prospective Study
14%
Receptor
14%
Neuroscience
Cognitive Disorders
28%
Dextro Aspartic Acid
14%
Low Density Lipoprotein Cholesterol
28%
Metabolic Pathway
14%
Proprotein Convertase 9
100%
Receptor Modulation
14%
Statin
14%